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Childhood purpura - Overview  
Purpura (from the Latin, purpura, meaning 
"purple") is the appearance of red or purple 
discolorations on the skin that do not blanch on 
applying pressure. They are caused by bleeding 
underneath the skin. Purpura measure 0.3-1cm, 
while petechiae measure less than 3mm and 
ecchymoses greater than 1cm1. The integrity of 
the vascular system depends on three interacting 
elements: platelets, plasma coagulation factors 
and blood vessels. All three elements are required 
for proper hemostasis, but the pattern of bleeding 
depends to some extent on the specific defect. In 
general, platelet disorders manifest petechiae, 
mucosal bleeding (wet purpura) or, rarely, central 
nervous system bleeding; coagulation disorders 
present as ecchymoses or hemarthrosis; and 
vasculitic disorders present with palpable 
purpura2. Purpura may be secondary to 
thrombocytopenia, platelet dysfunction, 
coagulation factor deficiency or vascular defect as 
shown in table 1.  
A thorough history (Table 2) and a careful 
physical examination (Table 3) are critical first 
steps in the evaluation of children with purpura3. 
When the history and physical examination 
suggest the presence of a bleeding disorder, 
laboratory screening studies may include a 
complete blood count, peripheral blood smear, 
prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). With few exceptions, 
these studies should identify most hemostatic 
defects (Figure 1)4. 
 
Table 1: Etiology of childhood purpura. 
 
Pathogenesis Etiology 
I-Platelet disorders  









b) Non immune destruction 
 
c) Decreased  platelet production 
-Congenital syndromes 




















Drugs (penicillin, valproic acid, quinidine, sulfonamides, cimetidine and 
heparin.) 
Infections (immunodeficiency virus, cytomegalovirus and herpesvirus)  
Connective tissue diseases (systemic lupus erythematosus) 
Post-transfusion 
Neonatal allo- and iso-immunization  
Hemolytic-uremic syndrome 
Thrombotic thrombocytopenic purpura  
Disseminated intravascular coagulopathy. 
 
Thrombocytopenia absent radii (TAR) syndrome 
Fanconi anemia 
Wiskott-Aldrich syndrome 
Congenital amegakaryocytic thrombocytopenia 
Drugs (alkylating agents, antimetabolites, anticonvulsants, chlorothiazide  
diuretics and estrogens)  
 Infections (TORCH, septicemia) 
 Malignancies (leukemia, histiocytosis, neuroblastoma,) 













II- Vascular factors  
a) Congenital causes  
 




Hereditary hemorrhagic telangiectasia 
Ehlers-Danlos syndrome 
Henoch-Schönlein purpura,  
Drugs (atropine and chloral hydrate)  
Infections (measles, scarlet fever, typhoid, meningococcemia, rickettsial  
diseases)  
Mechanical (violent coughing, vomiting, child abuse) Psychogenic 
conditions. 
III- Coagulation factor deficiencies 
a) Hereditary 




Disseminated intravascular coagulopathy,  
Circulating anticoagulants,  
Liver disease,  
Vitamin K deficiency, uremia. 




Table 2: Findings of the history and possible etiologies of purpura. 
 
Historical data Possible etiology 
Age of Onset  
Birth Intrauterine infection, maternal idiopathic thrombocytopenic 
purpura, maternal systemic lupus erythematosus, maternal 
medication, TAR syndrome, congenital amegakaryocytic 
thrombocytopenia  
2 to 4 years Idiopathic thrombocytopenic purpura  
4 to 7 years Henoch-Schönlein purpura  
Onset/chronicity  
Acute onset Idiopathic thrombocytopenic purpura, Henoch-Schönlein  
purpura, medication, mechanical cause  
Long duration Abnormality of platelets, coagulopathy  
Pattern of bleeding   
Mucosal bleeding Thrombocytopenia, von Willebrand's disease  
Intramuscular and intra-articular bleeding Hemophilia 
Associated symptoms   
Abdominal pain, blood in stools, joint pain Henoch-Schönlein purpura  
Lethargy, fever, bone pain Leukemia  
Intermittent fever, musculoskeletal symptoms Systemic lupus erythematosus 
Lethargy, polyuria, polydipsia, failure to thrive Uremia 
Purpura, but otherwise healthy Idiopathic thrombocytopenic purpura 
Drug use   
Alkylating agents Thrombocytopenia 
Antimetabolites Thrombocytopenia  
Past health   
Antecedent viral infection, especially an upper 
respiratory tract infection 
Idiopathic thrombocytopenic purpura, Henoch-Schönlein purpura 
Systemic lupus erythematosus Systemic lupus erythematosus 
Liver disease Cirrhosis or chronic hepatitis  
Renal disease Chronic renal failure  
Family history   
von Willebrand's disease von Willebrand's disease 
TAR syndrome TAR syndrome 
Wiskott-Aldrich syndrome  Wiskott-Aldrich syndrome  
Maternal history   
Maternal idiopathic thrombocytopenic purpura  Immune thrombocytopenia 
Maternal systemic lupus erythematosus  Immune thrombocytopenia 
(Leung and Chan, 2001)3. 
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Table 3: Physical findings and possible etiologies of purpura. 
 
Physical findings Possible etiology 
General findings  
Poor growth  Chronis disorder 
Fever  Infection  
hypertension Chronic renal failure, renal vasculitis 
Characteristics of purpura  
Location on lower extremities Henoch-Schönlein purpura 
Location on palms and soles Rickettsial infection 
Palpable purpura Vasculitis  
Associated signs  
Arthritis, abdominal tenderness, subcutaneous edema, scrotal swelling Henoch-Schönlein purpura 
Hemarthrosis  Hemophilia 
Butterfly rash, pallor, arthritis, lymphadenopathy Systemic lupus erythematosus 
Lymphadenopathy  Infection, drugs, malignancy 
Jaundice, spider angioma, palmar erythema, hepatosplenomegaly Liver disease 
Pallor, lethargy, generalized bone tenderness, hepatosplenomegaly, 
lymphadenopathy 
Leukemia  
Skeletal anomalies TAR syndrome, Fanconi's syndrome 
Pallor, café au lait spots, short stature Fanconi's syndrome 
Telangiectasia Hereditary hemorrhagic telangiectasia 
Hyperelasticity of skin, hypermobility of joints Ehlers-Danlos syndrome 






(PT = prothrombin time; aPTT = activated partial thromboplastin time) 
 




Patho-physiology of immune purpura  
Immune thrombocytopenic purpura (ITP):  
The appearance of antibodies against blood cells, 
including platelets, is often associated with viral 
infections. Viral disease may change the complex 
immune response of the host at different levels. 
Antigen-presenting cells may be disturbed; T cells 
may be influenced by altered cytokine production 
and release, thus disturbing further activation of the 
network of the immune system; B cells may 
produce increased amounts of antibodies and, as 
one of the consequences, the feedback mechanism 
of the immune system may be dysregulated5.   
For example, Epstein-Barr viruses (EBV) 
stimulate B lymphocytes to enhanced production of 
antibodies which cross-react with normal tissue 
proteins exhibiting configurations similar to those 
of the infectious agent6. This corresponds to 
molecular mimicry. Agranulocytosis due to EBV 
infection has been observed also in conjunction 
with bone marrow hypoplasia7. Cytomegalovirus 
(CMV) protein is similar to the human leucocyte 
antigen (HLA)-DR β-chain protein, and shares a 
common epitope with it8. Thrombocytopenia has 
been observed in both congenital and acquired 
CMV infection. CMV infection is known to induce 
multiple autoantibodies9, and human CMV can 
suppress haematopoiesis10. Human parvovirus 
(B19) inhibits hematopoietic colony formation in 
vitro. Thrombocytopenia, neutropenia and 
erythrocytopenia, as well as pancytopenia due to 
parvovirus infection, have been reported11.  
Evidence for platelet destruction in ITP 
includes the following: (1) infusion of ITP blood or 
plasma into normal recipients may result in 
thrombocytopenia; (2) there is decreased 
intravascular survival of radiolabeled platelets in 
most ITP patients; (3) morphologic and in vitro 
evidence of platelet phagocytosis can be 
demonstrated; and (4) cytotoxic T cells can induce 
lysis of autologous platelets. Evidence for 
suppressed platelet production in ITP includes the 
following: (1) morphologic studies show 
megakaryocyte damage in most ITP patients; (2) 
there is normal or decreased platelet turnover in the 
majority of patients; (3) in vitro studies show 
antibody-induced inhibition of megakaryocyte 
production and maturation; and (4) an increase in 
the platelet count occurs in many ITP patients 
receiving treatment with thrombopoietin 
mimetics12. 
There is laboratory evidence that platelet 
alloantibodies decrease platelet reactivity to 
selected agonists. Deficient platelet function 
underlying immune thrombocytopenia may 
contribute to bleeding tendency seen at similar 
platelet levels13. The principle of downregulation of 
platelet function by antibodies has been used in 
producing monoclonal antibodies for clinical use14. 
ITP can be classified as primary (known also as 
idiopathic thrombocytopenic purpura) or as 
secondary to an underlying condition such as a 
malignant or nonmalignant disorder.  
Primary ITP is caused by an inappropriate 
response of the immune system usually following a 
viral infection or immunization. Although ITP is 
primarily mediated by IgG autoantibodies, the 
production of these autoantibodies is regulated by 
the influence of T lymphocytes and antigen-
presenting cells (APC). There is evidence that 
enhanced T-helper cell/APC interactions in patients 
with ITP may play an integral role in IgG 
antiplatelet autoantibody production15. Some 
patients have evidence of oligoclonality whereas 
others have polyclonal autoantibodies16.  
ITP patients develop autoantibodies that bind to 
platelet antigens (such a glycoprotein IIb/IIIa 
(GPIIb/IIa) or GPIb/IX)17. Many patients produce 
multiple antibodies; this has been attributed to the 
phenomenon of epitope spreading (figure 2). Once 
produced, autoantibody may either bind to platelets, 
causing their destruction by either phagocytosis or 
possibly complement activation and lysis, or bind to 
megakaryocytes, resulting in decreased 
thrombopoiesis12. Immune-mediated clearance of 
particles via the reticuloendothelial system (RES) is 
a function of immunoglobulin class, complement 
activation, and specific effector cells within the 
RES18,19.  
Three discrete pathways may result in the 
destruction of antibody-coated platelets. In one 
path-way, the direct activation of the complement 
cascade results in the formation of a membrane 
attack complex that produces pores in the platelet 
membrane and subsequent platelet lysis. Platelet 
destruction may also occur via engagement of 
complement receptors (CR1), Fcγ receptors (FcγR), 
or both20-21. Fcγ chain deficient mice cannot 
develop ITP22, and ITP is palliated by therapy with 
anti-FcγR antibodies23 and Fcγ fragments of 
intravenous immunoglobulin24. Several studies have 
shown that ITP patients demonstrate elevated levels 
of platelet-associated C3, C4, and C9, suggesting in 
vivo complement activation25, and some of the 
effects of IVIG may occur by reducing C3 and C4 
deposition on platelets26. Additionally, it has been 
suggested that FcγR-mediated platelet elimination 
most likely occurs in the spleen and that 
complement-mediated platelet elimination most 
likely occurs in the liver; as such, complement-
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mediated platelet elimination may be of particular 
importance in splenectomized ITP patients. The 
competitive blockade of Fcγ R reduces Fcγ R-
mediated elimination of platelets, thereby 
increasing platelet counts in ITP27. This is the basis 
of present anti-D and possible future treatments like 
antibody-coated liposomes28.  
Secondary ITP: Commonly occurring conditions 
associated with secondary ITP include 
lymphoproliferative disorders (Hodgkin's disease 
and non-Hodgkin's lymphomas), autoimmune 
collagen vascular diseases (systemic lupus 
erythematosus [SLE], thyroid disease, 
antiphospholipid syndrome [APS]), and chronic 
infections (human immunodeficiency virus [HIV], 
helicobacter pylori and hepatitis C virus [HCV])5.  
The mechanism of platelet destruction in 
thrombocytopenias associated with 
lymphoproliferative disorders and collagen vascular 
diseases is identical to the autoimmune mechanism 
seen in primary ITP. Platelet destruction in 
infection-associated ITP occurs via various 
mechanisms including accelerated platelet clearance 
due to immune complex disease as seen in HIV 
infection or cross-reactivity of anti-platelet 
glycoprotein antibodies and viral antigens in HIV, 
HCV, and H pylori infections (antigenic mimicry). 
In patients with HCV-related cirrhotic liver disease, 
splenic sequestration secondary to portal 
hypertension and decreased production of 
thrombopoietin may further contribute to 
development of thrombocytopenia29. 
  
Neonatal allo immune thrombocytopenia (NAT) is 
a life-threatening bleeding disorder caused by 
maternal platelet antibodies produced in response to 
fetal platelet antigens (platelet-specific alloantigens) 
inherited from the father30. Antiplatelet antibodies 
cross the placenta and cause destruction of fetal 
platelets, leading to severe thrombocytopenia, and 
potentially bleeding, including fatal intracerebral 
hemorrhage. Among platelet-specific alloantigens, 
Human Platelet Antigen (HPA) 1a is by far the 
most commonly involved in NAT in Caucasians31, 
followed, at a much lower frequency, by HPA 5b32. 
In Asians, NAT is essentially linked with HPA-4 
system. Other cases have been reported due to rare 
or private alloantigens33-36.  Diagnostic testing for 
NAT involves genotyping of maternal, paternal, 
and sometimes fetal DNA; platelet antigen 
phenotyping; and maternal platelet antibody 
investigations using specialized platelet 
glycoprotein specific assays37. 
Meningococcal sepsis in children develops when 
the initial host response to the infection becomes 
inappropriately amplified and dysregulated. After 
the development of the first petechiae, the patient 
rapidly deteriorates and may subsequently develop 
shock, disseminated intravascular coagulation 
(DIC), and ultimately organ failure38,39. Interferon-
alpha (INF- α) levels are raised in all patients with 
meningococcal disease and there is a positive 
correlation between their levels and severity scores, 
coagulopathies (including DIC), and outcome40.  
 
Drug-induced thrombocytopenia; Many drugs are 
capable of causing antibody-mediated 
thrombocytopenia. Some drugs become bound 
covalently to platelet membrane glycoproteins in 
vivo and stimulate the production of hapten-
dependent antibodies that recognize drug-
membrane protein targets. Others, such as 
quinidine, quinine, and sulfonamide antibiotics, 
induce the formation of an unusual class of 
antibodies that bind to membrane glycoproteins 
only when the drug (or one of its metabolites) is 
present in solution. Certain drugs trigger the 
production of true autoantibodies capable of 
binding to cell membrane glycoproteins in the 
absence of drug41. Heparin-induced immune 
thrombocytopenia (HIT) is associated with 
antibodies specific for complexes formed between 
heparin and platelet factor 4 (PF4), a basic protein 
of the chemokine family found normally in platelet 
alpha granules. Immune complexes consisting of 
heparin, PF4, and antibodies are important in the 
pathogenesis of HIT42. For many drug-induced 
thrombocytopenias, the targeted membrane 
glycoproteins are readily accessible for laboratory 
investigation and methods for detecting the 
responsible antibodies are well developed. Studies 
of drug-induced ITP may provide clues to the 
general mechanisms whereby drugs and other 
xenobiotics induce immune diseases. Clinicians 
should consider the possibility of an exogenous 
trigger in patients who present with apparent 
autoimmune thrombocytopenia43.   
 
Vascular purpura    
Multiple mechanisms contribute to the pathogenesis 
of systemic vasculitides: 1. vasculitides resulting 
from the deposition of circulating immune 
complexes, comprising polyarteritis nodosa 
associated with hepatitis B virus infection, 
cryoglobulinemia associated systemic vasculitides, 
mainly the consequence of hepatitis C virus 
infection, and Schonlein Henoch purpura, which 
results from the deposition in the mesangium and 
vessels of IgA forming complexes;  2. vasculitides 
associated with anti-neutrophil cytoplasm 
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antibodies (ANCA), comprising Wegener's 
granulomatosis associated with anti-proteinase 3 
ANCA, and microscopic polyangiitis and Churg-
Strauss syndrome, associated with anti-
myeloperoxidase ANCA. The pathogenic role of 
ANCA has been demonstrated in vitro and in vivo 
in the case of anti-myeloperoxidase antibodies, 
whereas it has only been demonstrated in vitro in 
the case of anti-proteinase 3 antibodies; 3. 
polyarteritis nodosa unrelated to viral infection 
results from rheologic phenomenon that explains 
the localisation of vasculitis lesions at the 
bifurcation of arteries and the presence of 
microaneurysm44. 
 
Schönlein-Henoch purpura (HSP) is a common 
vasculitis in children, characterized by the presence 
of immunoglobulin A (IgA) dominant immune 
deposits in the small vessels in skin, the 
gastrointestinal (GI) tract, the joints and sometimes 
the kidney45. Serum eosinophil cationic protein 
(ECP) levels have been shown to be significantly 
higher in children with HSP than those with IgA 
nephropathy or healthy controls. Serum levels of 
ECP were found to be even higher in HSP patients 
with nephritis compared to those without nephritis. 
Another recent study from Japan also found higher 
serum concentrations of ECP and interleukin (IL)-5 
in patients with HSP nephritis46. Another possible 
player are the IgA anti-neutrophilic cytoplasmic 
antibodies (ANCA), which have been detected in 
anywhere from 10% to 82% of patients with 
HSP47,48. Whether they have a role in the 
pathogenesis in HSP and HSP nephritis needs 
further investigation. Lastly, complement C4B 
deficiency has also been reported to be associated 
with severe HSP nephritis and could possibly have 
a pathogenic role49. 
 
Immune therapy of purpura  
Immune thrombocytopenic purpura: Acute and 
chronic ITP are benign conditions with a high 
probability of spontaneous recovery with or without 
therapy. Rates of 80-90% complete remission can 
be achieved irrespective of the treatment given. In 
only 10-20% of children, thrombocytopenia persists 
for more than six months, showing a chronic 
course, which also has a high probability of 
remitting over time (up to 80% or more). The 
variability of the clinical course, and the lack of 
consistent clinical features, make the decision on 
whether and how to treat difficult. Most physicians 
are driven to treat all children with symptoms by 
concern over life-threatening hemorrhage, although 
the risk of intracranial hemorrhage (ICH) is only 
0.1-0.9%50. It has been generally agreed that 
bleeding - not platelet count - should be the 
rationale for treatment. Despite the absence of 
prospective, controlled studies, there is consensus 
that bleeding risks are significantly greater in 
patients with platelet counts <20 x 109-30 x 109/L, 
and therefore treatment is indicated for these 
patients. For those with platelet counts that are 
higher, but still <50 x 109/L, treatment is also 
indicated if accompanied by substantial mucous 
membrane bleeding 51.  
Based on understanding antibody production 
and immune dysregulation (Figure 3) in ITP, the 
commonly used treatment regimens for acute ITP 
are corticosteroids, intravenous immunoglobulins 
(IVIG) (table 4), or intravenous anti-D 
immunoglobulin (anti-D). So far, there is no 
evidence that initial therapy can prevent ICH or a 
chronic course of the disease5,50.  
 
Table 4. Treatment of ITP with IVIG. 
   
Initial treatment 
Day 1: 0.8 g IVIG/kg body weight 
Day 3:  
• If platelet count is > 30 x 109 /1, no further 
treatment 
• If platelet count is < 30 x 109/1, repeat IVIG as 
on day 1 
• If platelet count is < 10 x 109/1, bone marrow 
analysis for exclusion of production disorders of 
platelets, leukemia, etc. 
Emergency treatment (severe bleeding, pre-
surgery) 1-2 x 1.0 g IVIG/kg body weight until 
platelet counts are at least > 30 x 109/l or there is 
no more bleeding. Eventually, combination with 
high-dose methyl prednisolone (8-12 mg/kg body 
weight, intravenously or orally) and/or with 
platelet transfusion 
Preventive treatment and treatment in chronic 
ITP (platelet count < 10-30 x 109/l) 0.4-0.8 g 
IVIG/kg body weight, once 
(Imbach et al., 1995)5. 
 
The standard initial treatment for ITP is oral 
corticosteroids to increase platelet counts. Excellent 
early responses to oral prednisone (4 mg per 
kilogram per day for four consecutive days) have 
also been reported in an uncontrolled prospective 
study52. Behavioral changes, weight gain, 
osteopenia, and glycosuria can occur during even 
brief courses of high-dose corticosteroids19. 
Intravenous immunoglobulin or anti-D 
immunoglobulin can also increase platelet counts 
and are particularly useful for stimulating rapid 
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platelet increases before planned procedures52. A 
single dose of intravenous immune globulin (0.8 g 
per kilogram) is generally effective53. Adverse 
reactions are generally transient and related to the 
rate of infusion; these include headache, fever, 
nausea, and rarely, aseptic meningitis that may 
arouse concern about the possibility of intracranial 
hemorrhage54. Renal failure and pulmonary 
insufficiency may occur, and anaphylaxis may 
occur in recipients who have a congenital deficiency 
of IgA19. A larger dose of anti-D immune globulin 
(75 µg per kilogram) evokes a response similar to 
intravenous immune globulin55. The average 
decrease in the hemoglobin level is 1.3 g per 
deciliter56 and intravascular hemolysis is rare57.  In 
presence of neurologic symptoms, internal 
bleeding, or emergency surgery, immediate 
intervention is demanded; Methylprednisolone (30 
mg per kilogram per day; maximum, 1.0 g per day 
for two to three days) should be administered 
intravenously over a period of 20 to 30 minutes58,59 
together with intravenous immune globulin (1 g per 
kilogram per day for two to three days) and an 
infusion of platelets that is two to three times the 
usual amount infused60. In relapse, if Rh-positive, 
anti-D immune globulin, if clinically effective, is 
preferred to intravenous immune globulin because 
of its ease of administration, similar efficacy, and 
lower cost19. 
In chronic ITP the same drugs are generally 
used and it seems that pulses with steroids may be 
just as effective as IVIG. Anti-D may also be 
considered a reliable and cheap alternative for 
chronic disease. A major problem in the 
management of chronic ITP is the question of 
whether repeated infusions of Ig (IVIG or anti-D) 
and/or corticosteroids, high-dose dexamethasone, 
intermittent anti-D immuno-globulin infusions, and 
rituximab can postpone or ultimately preclude 
splenectomy, which must be considered only for a 
small proportion of patients resistant to therapy. In 
these cases, a laparoscopic approach should be 
preferred. Children who fail to respond to 
splenectomy (<20% of cases) warrant second line 
treatment with an immunosuppressant that inhibits 
T- and B-cell function and cooperation, including 
azathioprine, cyclophosphamide, cyclosporine, 
mycophenolate mofetil, or anti-CD20, and deserve 
a revisit of diagnosis for exclusion of secondary 
ITP. Patients may be more responsive to these same 
modalities after splenectomy50-51. Therapy of 
chronic or refractory ITP with thrombopoietin, 
antiCD40 ligand antibody, and Helicobacter pylori 
eradication have been reported61. 
The standard initial treatment for ITP is oral 
corticosteroids to increase platelet counts. Excellent 
early responses to oral prednisone (4 mg per 
kilogram per day for four consecutive days) have 
also been reported in an uncontrolled prospective 
study52. Behavioral changes, weight gain, 
osteopenia, and glycosuria can occur during even 
brief courses of high-dose corticosteroids19. 
Intravenous immunoglobulin or anti-D 
immunoglobulin can also increase platelet counts 
and are particularly useful for stimulating rapid 
platelet increases before planned procedures52. A 
single dose of intravenous immune globulin (0.8 g 
per kilogram) is generally effective53. Adverse 
reactions are generally transient and related to the 
rate of infusion; these include headache, fever, 
nausea, and rarely, aseptic meningitis that may 
arouse concern about the possibility of intracranial 
hemorrhage54. Renal failure and pulmonary 
insufficiency may occur, and anaphylaxis may 
occur in recipients who have a congenital deficiency 
of IgA19. A larger dose of anti-D immune globulin 
(75 µg per kilogram) evokes a response similar to 
intravenous immune globulin55. The average 
decrease in the hemoglobin level is 1.3 g per 
deciliter56 and intravascular hemolysis is rare57.  In 
presence of neurologic symptoms, internal 
bleeding, or emergency surgery, immediate 
intervention is demanded; Methylprednisolone (30 
mg per kilogram per day; maximum, 1.0 g per day 
for two to three days) should be administered 
intravenously over a period of 20 to 30 minutes58,59 
together with intravenous immune globulin (1 g per 
kilogram per day for two to three days) and an 
infusion of platelets that is two to three times the 
usual amount infused60. In relapse, if Rh-positive, 
anti-D immune globulin, if clinically effective, is 
preferred to intravenous immune globulin because 
of its ease of administration, similar efficacy, and 
lower cost19. 
In chronic ITP the same drugs are generally 
used and it seems that pulses with steroids may be 
just as effective as IVIG. Anti-D may also be 
considered a reliable and cheap alternative for 
chronic disease. A major problem in the 
management of chronic ITP is the question of 
whether repeated infusions of Ig (IVIG or anti-D) 
and/or corticosteroids, high-dose dexamethasone, 
intermittent anti-D immunoglobulin infusions, and 
rituximab can postpone or ultimately preclude 
splenectomy, which must be considered only for a 
small proportion of patients resistant to therapy. In 
these cases, a laparoscopic approach should be 
preferred. Children who fail to respond to 
splenectomy (<20% of cases) warrant second line 
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treatment with an immunosuppressant that inhibits 
T- and B-cell function and cooperation, including 
azathioprine, cyclophosphamide, cyclosporine, 
mycophenolate mofetil, or anti-CD20, and deserve 
a revisit of diagnosis for exclusion of secondary 
ITP. Patients may be more responsive to these same 
modalities after splenectomy50-51. Therapy of 
chronic or refractory ITP with thrombopoietin, 
antiCD40 ligand antibody, and Helicobacter pylori 




Figure 2.  Pathogenesis of epitope spread in immune thrombocytopenic purpura 




Figure 3. Mechanisms of action of therapies for immune thrombocytopenic purpura 
(From Cines and Blanchette, 2002)19. 
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